Inno.N-National Cancer Center Collaborate on Big Data-Driven Anticancer Drug Research

Inno.N and the National Cancer Center have joined forces to conduct anticancer drug research using big data. After the "Data Provision Cooperation Agreement (MOU) Signing Ceremony for Promoting New Drug Development Using Cancer Big Data Platform" held on the 26th, officials are taking a commemorative photo. (Photo by National Cancer Center)

[Asia Economy Reporter Chunhee Lee] Inno.N and the National Cancer Center have joined forces to conduct anticancer drug research using big data.

On the 26th, Inno.N announced that it signed a 'Data Provision Cooperation Memorandum of Understanding (MOU) for Promoting New Drug Development Using the Cancer Big Data Platform' with the National Cancer Center Cancer Big Data Platform Project Group and Jeonbuk National University Hospital Jeonbuk Big Data Center.

The cancer big data platform 'CONNECT' is a cancer-specialized multi-institutional clinical library platform being established at 11 healthcare platform centers including the National Cancer Center. It allows research use of clinical data for a total of 10 types of cancers such as breast cancer, thyroid cancer, ovarian cancer, and lung cancer.

Through this agreement, Inno.N will utilize CONNECT to develop targeted anticancer drugs by classifying target patients, developing biomarkers (internal indicators), selecting clinical trial institutions, and recruiting subjects. The National Cancer Center Cancer Big Data Platform Project Group will support new drug development using CONNECT, and the Jeonbuk Big Data Center will focus on building clinical data by cancer type while supporting smooth data utilization.

The first projects to apply the big data secured through this agreement by Inno.N are a selectively developed RET inhibitor series targeted anticancer drug (project name IN-A013) and a next-generation EGFR inhibitor series targeted anticancer drug (project name IN-A008), both currently under development.

Geunseok Song, Executive Vice President of Research and Development (R&D) at Inno.N, said, “Although domestic companies have many needs for big data services, access has not been easy. Utilizing cancer big data will not only improve research accuracy and efficiency but is also expected to elevate Inno.N’s anticancer drug development capabilities to the next level.”

Daeyong Kim, Head of the National Cancer Center Cancer Big Data Platform Project Group, also stated, “By combining cancer big data with customized diagnostic systems and targeted anticancer drug development technologies, we can improve the inefficiencies in new drug development and take a step closer to global anticancer drug development.”

This content was produced with the assistance of AI translation services.